A detailed history of Jpmorgan Chase & CO transactions in Natera, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 7,357,916 shares of NTRA stock, worth $783 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
7,357,916
Previous 7,954,212 7.5%
Holding current value
$783 Million
Previous $498 Million 35.06%
% of portfolio
0.06%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$59.21 - $92.9 $35.3 Million - $55.4 Million
-596,296 Reduced 7.5%
7,357,916 $673 Million
Q4 2023

Feb 12, 2024

BUY
$37.55 - $62.64 $14.9 Million - $24.9 Million
397,420 Added 5.26%
7,954,212 $498 Million
Q3 2023

Nov 14, 2023

BUY
$43.4 - $62.52 $28 Million - $40.3 Million
644,102 Added 9.32%
7,556,792 $334 Million
Q2 2023

Aug 11, 2023

BUY
$47.08 - $55.16 $12.6 Million - $14.7 Million
267,357 Added 4.02%
6,912,690 $336 Million
Q1 2023

May 18, 2023

BUY
$36.57 - $58.29 $2.22 Million - $3.54 Million
60,777 Added 0.92%
6,645,333 $369 Million
Q1 2023

May 11, 2023

BUY
$36.57 - $58.29 $14 Million - $22.3 Million
381,844 Added 6.16%
6,584,556 $366 Million
Q4 2022

Feb 13, 2023

BUY
$34.17 - $47.91 $21.6 Million - $30.3 Million
632,340 Added 11.35%
6,202,712 $249 Million
Q3 2022

Nov 14, 2022

BUY
$36.93 - $56.68 $3.6 Million - $5.53 Million
97,593 Added 1.78%
5,570,372 $244 Million
Q2 2022

Aug 11, 2022

BUY
$28.13 - $44.54 $13.1 Million - $20.8 Million
466,500 Added 9.32%
5,472,779 $194 Million
Q1 2022

May 11, 2022

SELL
$30.32 - $91.33 $2.21 Million - $6.65 Million
-72,812 Reduced 1.43%
5,006,279 $204 Million
Q4 2021

Feb 10, 2022

BUY
$86.26 - $119.0 $30.7 Million - $42.3 Million
355,574 Added 7.53%
5,079,091 $474 Million
Q3 2021

Nov 12, 2021

BUY
$100.17 - $126.36 $473 Million - $597 Million
4,723,517 New
4,723,517 $526 Million

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $10.3B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.